GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

医学 肝硬化 疾病 脂肪肝 内科学 肝病 胃肠病学
作者
Fasiha Kanwal,Jennifer R. Kramer,Liang Li,Yu‐Xiao Yang,Yumei Cao,Xian Yu,Ronald Samuel,Basim Ali,Roxanne Desiderio,George Cholankeril,Mandeep Bajaj,Hashem B. El‐Serag,Steven M. Asch
出处
期刊:JAMA Internal Medicine [American Medical Association]
标识
DOI:10.1001/jamainternmed.2024.4661
摘要

Importance Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing cause of cirrhosis. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in improving liver inflammation in patients with MASLD. Objective To determine whether use of GLP-1 RAs is associated with lower risk of developing cirrhosis and its complications, including decompensation and hepatocellular cancer (HCC), among patients with MASLD. Design, Setting, and Participants This retrospective cohort study with an active comparator, new-user design used data from the national Veterans Health Administration Corporate Data Warehouse and Central Cancer Registry. Patients with MASLD and diabetes who were seen at 130 Veterans Health Administration hospitals and associated ambulatory clinics and who initiated either a GLP-1 RA or dipeptidyl peptidase 4 inhibitor (DPP-4i) between January 1, 2006, and June 30, 2022, were included. Patients were followed up from baseline until one of the study outcomes or the end of the study period (December 31, 2022), whichever came first. Exposures Each GLP-1 RA new user was propensity score matched in 1:1 ratio to a patient who initiated a DPP-4i during the same month. Separate analyses were conducted among patients without and with cirrhosis at baseline. Main Outcomes and Measures For patients without cirrhosis, the primary outcome was progression to cirrhosis defined by validated diagnoses codes or a noninvasive marker of liver fibrosis, and secondary outcomes were cirrhosis complications defined both as a composite and individual complications, including decompensation, HCC, or liver transplant, and all-cause mortality. For patients with cirrhosis, the primary outcome was a composite outcome of cirrhosis complications, and secondary outcomes were decompensation, HCC, and all-cause mortality. Results Of 16 058 patients who initiated GLP-1 RAs, 14 606 did not have cirrhosis (mean [SD] age, 60.56 [10.31] years; 13 015 [89.1%] male), and 1452 had cirrhosis (mean [SD] age, 66.99 [7.09] years; 1360 [93.7%] male) at baseline. These patients were matched to an equal number of patients who initiated a DPP-4i. In patients without cirrhosis, GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of cirrhosis (9.98 vs 11.10 events per 1000 person-years; hazard ratio [HR], 0.86; 95% CI, 0.75-0.98). Similar results were seen for the secondary outcomes. GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of the composite outcome of cirrhosis complications (1.89 vs 2.55 events per 1000 person-years; HR, 0.78; 95% CI, 0.59-1.04) and mortality (21.77 vs 24.43 events per 1000 person-years; HR, 0.89; 95% CI, 0.81-0.98). There were no associations between GLP-1 RA use and outcomes in patients with cirrhosis. Conclusions and Relevance In this cohort study, GLP-1 RA use was associated with a lower risk of progression to cirrhosis and mortality among patients with MASLD and diabetes. The protective association was not seen in patients with existing cirrhosis, underscoring the importance of treatment earlier in the disease course.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
优秀老师发布了新的文献求助10
1秒前
1秒前
1秒前
科研小子发布了新的文献求助10
2秒前
友好的鲜花完成签到,获得积分10
2秒前
2秒前
nns完成签到,获得积分10
2秒前
4秒前
4秒前
liyyyyy完成签到,获得积分20
4秒前
4秒前
4秒前
4秒前
Johnson发布了新的文献求助30
4秒前
MOD完成签到,获得积分10
5秒前
5秒前
现代的秋发布了新的文献求助10
6秒前
当当羊.发布了新的文献求助10
6秒前
王俊完成签到,获得积分20
7秒前
MOD发布了新的文献求助10
7秒前
JamesPei应助小杰采纳,获得10
7秒前
干不动了完成签到,获得积分10
7秒前
英姑应助机智水杯采纳,获得10
8秒前
HaniRxf发布了新的文献求助20
8秒前
王俊发布了新的文献求助10
9秒前
闲听花落发布了新的文献求助10
9秒前
勤劳悒发布了新的文献求助10
9秒前
小陈完成签到,获得积分10
10秒前
10秒前
孤独孤风发布了新的文献求助10
10秒前
Ava应助昵称采纳,获得10
11秒前
13秒前
FashionBoy应助优秀老师采纳,获得10
13秒前
郎治宇发布了新的文献求助10
13秒前
13秒前
14秒前
乐乐应助勤劳悒采纳,获得10
15秒前
15秒前
可爱的函函应助大气晓霜采纳,获得10
16秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3160303
求助须知:如何正确求助?哪些是违规求助? 2811427
关于积分的说明 7892391
捐赠科研通 2470463
什么是DOI,文献DOI怎么找? 1315585
科研通“疑难数据库(出版商)”最低求助积分说明 630884
版权声明 602038